Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer

By tstorla Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm, Sweden. The targeted agent delayed the progression of metastatic disease, reduced the risk of death, and delayed the start of

Read more